Chinese clinical-stage biopharma firm Akeso has resubmitted a draft prospectus with the Hong Kong stock exchange on Monday, exactly two months after the city board rejected its original application for an initial public offering (IPO).
Sponsored by Morgan Stanley and JP Morgan Securities, the $300-million IPO application of Akeso was rejected by the HKEX on December 5, 2019. The bourse did not provide a reason.
